S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Sick of seeing others get rich in the stock market? Let Stock Advisor help (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
The 3-Stock Retirement Blueprint (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
The 3-Stock Retirement Blueprint (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Sick of seeing others get rich in the stock market? Let Stock Advisor help (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
The 3-Stock Retirement Blueprint (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
The 3-Stock Retirement Blueprint (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Sick of seeing others get rich in the stock market? Let Stock Advisor help (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
The 3-Stock Retirement Blueprint (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
The 3-Stock Retirement Blueprint (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Sick of seeing others get rich in the stock market? Let Stock Advisor help (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
The 3-Stock Retirement Blueprint (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
The 3-Stock Retirement Blueprint (Ad)
NASDAQ:SMMT

Summit Therapeutics - SMMT Stock Forecast, Price & News

$1.04
+0.07 (+7.22%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.93
$1.06
50-Day Range
$0.89
$1.18
52-Week Range
$0.88
$8.39
Volume
80,245 shs
Average Volume
143,331 shs
Market Capitalization
$102.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SMMT stock logo

About Summit Therapeutics (NASDAQ:SMMT) Stock

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Summit Therapeutics Stock Down 3.4 %

Shares of NASDAQ:SMMT opened at $0.97 on Wednesday. The firm's fifty day moving average is $1.03 and its 200 day moving average is $1.72. Summit Therapeutics has a 52 week low of $0.88 and a 52 week high of $8.39. The company has a market cap of $94.79 million, a price-to-earnings ratio of -1.00 and a beta of 1.05.

Summit Therapeutics (NASDAQ:SMMT - Get Rating) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.22) earnings per share (EPS) for the quarter. The firm had revenue of $5.06 million during the quarter. Summit Therapeutics had a negative return on equity of 100.17% and a negative net margin of 735.61%.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Summit Therapeutics in a research report on Tuesday. They set a "sell" rating on the stock.

Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMMT Stock News Headlines

SMMT Summit Therapeutics Inc.
Summit Therapeutics Inc. Common Stock (SMMT)
See More Headlines
Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMMT Company Calendar

Last Earnings
11/15/2021
Today
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SMMT
Employees
105
Year Founded
N/A

Profitability

Net Income
$-88,600,000.00
Net Margins
-735.61%
Pretax Margin
-735.61%

Debt

Sales & Book Value

Annual Sales
$22.78 million
Book Value
$0.85 per share

Miscellaneous

Free Float
19,615,000
Market Cap
$102.05 million
Optionable
Optionable
Beta
1.05

Key Executives

  • Mr. Robert W. Duggan (Age 78)
    Co-CEO & Exec. Chairman
  • Dr. Mahkam Zanganeh D.D.S. (Age 52)
    M.B.A., MBA, Co-CEO, Pres & Director
    Comp: $651.45k
  • Dr. Urte Gayko Ph.D. (Age 51)
    Head of Regulatory Affairs, Quality Assurance & Safety and Director
    Comp: $7.76k
  • Prof. Dame Kay Davies DBE (Age 71)
    FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
  • Mr. Ankur Dhingra (Age 46)
    Chief Financial Officer
  • Ms. Michelle Avery
    Director of Investor Relations
  • Mr. Dave Gancarz
    Head of Investor Relations & Corp. Strategy
  • Dr. Elaine Stracker (Age 61)
    Gen. Counsel?
  • Mr. Campbell Hair
    Head of HR?
  • Dr. Anne Heatherington
    Head of Clinical Devel. and Quantitative Sciences













SMMT Stock - Frequently Asked Questions

Should I buy or sell Summit Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SMMT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SMMT, but not buy additional shares or sell existing shares.
View SMMT analyst ratings
or view top-rated stocks.

How have SMMT shares performed in 2022?

Summit Therapeutics' stock was trading at $2.69 on January 1st, 2022. Since then, SMMT shares have decreased by 61.0% and is now trading at $1.05.
View the best growth stocks for 2022 here
.

When is Summit Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our SMMT earnings forecast
.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) released its earnings results on Monday, November, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.09. The firm earned $6.12 million during the quarter. Summit Therapeutics had a negative net margin of 735.61% and a negative trailing twelve-month return on equity of 100.17%.

What other stocks do shareholders of Summit Therapeutics own?

When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Hoylecohen LLC (0.03%). Insiders that own company stock include David Jonathan Powell, Maky Zanganeh and Robert W Duggan.
View institutional ownership trends
.

How do I buy shares of Summit Therapeutics?

Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Summit Therapeutics' stock price today?

One share of SMMT stock can currently be purchased for approximately $1.05.

How much money does Summit Therapeutics make?

Summit Therapeutics (NASDAQ:SMMT) has a market capitalization of $103.03 million and generates $22.78 million in revenue each year. The company earns $-88,600,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis.

How many employees does Summit Therapeutics have?

The company employs 105 workers across the globe.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The official website for the company is www.summitplc.com. The company can be reached via phone at 617-514-7149, via email at investors@summitplc.com, or via fax at 44-12-3544-3999.

This page (NASDAQ:SMMT) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.